Standard BioTools Inc. announced preliminary and unaudited revenue results for the fourth quarter and full year 2025, reporting fourth quarter combined company revenue of approximately $56 million and revenue from continuing operations of about $24 million. For the full year 2025, combined company revenue is expected to reach approximately $185 million, with revenue from continuing operations around $85 million. The company ended the year above its guidance range and exceeded expectations for both combined and continuing operations. Leadership noted that targeted actions to streamline the organization and improve cost structure contributed to a stronger foundation and a leaner, more resilient business. Looking ahead to 2026, the company anticipates having approximately $550 million in cash following the sale of SomaLogic, with the base business progressing toward positive adjusted EBITDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9622015) on January 08, 2026, and is solely responsible for the information contained therein.